Objective: To explore the efficacy of Reduning injection combined with oseltamivir in the treatment of influenza A in children and its influence on the levels of high-sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6). Methods: A total of 106 children with influenza A admitted to Yanling County People’s Hospital from February 2023 to February 2025 were selected as research subjects, and were divided into conventional group and combined group by random number table method. Patients in the conventional group were given oral administration of oseltamivir (according to body weight: 30 mg·time-1 for ≤15 kg; 45 mg·time-1 for 15-23 kg; 60 mg·time-1 for 23-40 kg; 75 mg·time-1 for >40 kg) twice a day, and patients in the combined group were treated with Reduning injection (0.5 ml·kg-1, maximum dose≤10 mL) dissolved in 5% glucose injection by intravenous drip once a day for 5 days while receiving the treatment regimen of the conventional group. After 5 days of treatment, the clinical efficacy in the two groups was observed. The disappearance durations of fever, cough and swollen sore throat in the two groups were recorded and compared. Before treatment and after 5 days of treatment, the level of hs-CRP in the two groups was detected by immunoturbidimetry and IL-6 level was measured by enzyme-linked immunosorbent assay. Adverse reactions were observed during treatment (5 days). Results: Combined group demonstrated a higher overall response rate of treatment than conventional group (P<0.05). The disappearance durations of fever, cough and swollen sore throat were shorter in combined group compared to conventional group (P<0.05). After 5 days of treatment, both groups showed significant decreases in hs-CRP and IL-6 levels compared to before treatment (P<0.05), with combined group exhibiting lower levels than conventional group (P<0.05). The incidence rates of adverse reactions in combined group were higher compared with those in conventional group (P>0.05). Conclusion: Reduning injection combined with oseltamivir can effectively enhance the clinical efficacy in children with influenza A, accelerate the symptom relief, and reduce the inflammation level, with good safety.